MX2011013453A - Agentes antimicrobianos. - Google Patents

Agentes antimicrobianos.

Info

Publication number
MX2011013453A
MX2011013453A MX2011013453A MX2011013453A MX2011013453A MX 2011013453 A MX2011013453 A MX 2011013453A MX 2011013453 A MX2011013453 A MX 2011013453A MX 2011013453 A MX2011013453 A MX 2011013453A MX 2011013453 A MX2011013453 A MX 2011013453A
Authority
MX
Mexico
Prior art keywords
relates
present
gram
nucleic acid
acid molecules
Prior art date
Application number
MX2011013453A
Other languages
English (en)
Inventor
Stefan Miller
Original Assignee
Lysando Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lysando Holding Ag filed Critical Lysando Holding Ag
Publication of MX2011013453A publication Critical patent/MX2011013453A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a agentes antimicrobianos contra bacterias Gram-positivas, en particular a proteínas de fusión compuestas de una enzima que tiene la actividad de degradar la pared celular de bacterias Gram-positivas y a un tramo de péptido adicional fusionado a la enzima en el extremo N o C. Además, la presente invención se refiere a moléculas de ácido nucleico que codifican para la proteína de fusión, a vectores que comprenden las moléculas de ácido nucleico y a células hospederas que comprenden ya sea las moléculas de ácido nucleico o los vectores. Además, la presente invención se refiere a la proteína de fusión para usarse como un medicamento, en particular para el tratamiento o prevención de infecciones por bacterias Gram-positivas, como medio de diagnóstico o como sustancia cosmética. La presente invención se refiere también al tratamiento o prevención de la contaminación por bacterias Gram-positivas de productos alimenticios, de equipo de procesamiento de alimentos, de plantas procesadoras de alimentos, de superficies que entran en contacto con alimentos, de dispositivos médicos, de superficies en hospitales y quirófanos. Además, la presente invención se refiere a una composición farmacéutica que comprende la proteína de fusión.
MX2011013453A 2009-06-26 2010-06-28 Agentes antimicrobianos. MX2011013453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09163955 2009-06-26
PCT/EP2010/059152 WO2010149795A1 (en) 2009-06-26 2010-06-28 Antimicrobial agents

Publications (1)

Publication Number Publication Date
MX2011013453A true MX2011013453A (es) 2012-04-11

Family

ID=42537604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013453A MX2011013453A (es) 2009-06-26 2010-06-28 Agentes antimicrobianos.

Country Status (13)

Country Link
US (2) US20120195872A1 (es)
EP (2) EP3363896A1 (es)
JP (2) JP6034188B2 (es)
KR (1) KR101701890B1 (es)
CN (1) CN102482655B (es)
AU (1) AU2010264659B2 (es)
BR (1) BRPI1015203B1 (es)
CA (1) CA2765810C (es)
EA (1) EA038542B1 (es)
IL (1) IL217121B (es)
MX (1) MX2011013453A (es)
SG (1) SG177704A1 (es)
WO (1) WO2010149795A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170024129A (ko) 2009-06-26 2017-03-06 카톨리에케 유니버시테이트 루벤 항균제
KR101701890B1 (ko) 2009-06-26 2017-02-02 뤼산도 아게 항균제
MX2012002216A (es) 2009-08-24 2012-04-10 Univ Leuven Kath Nueva endolisina obpgplys.
JP6058540B2 (ja) * 2010-09-17 2017-01-11 テクニファー−インダストリア テクニカ ファーマシューティカ，エス．エー． 抗菌性ファージ、ファージペプチド、及びそれらの使用方法
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
CN102766196B (zh) * 2011-05-06 2014-10-29 上海医药工业研究院 一组阳离子抗菌肽及其制备方法和应用
CN103361341B (zh) * 2012-03-26 2015-09-02 复旦大学附属华山医院 杀菌肽ll-37的基因工程的表达及其制备方法和用途
EP2679232A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria vaccination
EP2679677A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
US9388400B2 (en) 2012-06-29 2016-07-12 Lysando Ag Composition for use in mycobacteria diagnosis
CN105579053B (zh) * 2013-08-06 2021-08-31 达特茅斯学院理事会 非糖基化溶葡球菌素变体蛋白
WO2015070911A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified kz144 endolysin sequence
WO2015070912A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence
EP2904912A1 (en) * 2014-02-07 2015-08-12 Hyglos Invest GmbH Novel high pressure method with endolysin for processing of foods
US10329550B2 (en) 2014-02-14 2019-06-25 Lysando Ag Antimicrobial agents
WO2016029920A1 (en) * 2014-08-29 2016-03-03 Aarhus Universitet Positively charged co-polymers for use as antimicrobial agents
WO2016130024A1 (en) * 2015-02-13 2016-08-18 Supreme Biotechnologies Limited Endolysin expression platform
CA3022334A1 (en) * 2016-04-28 2017-11-02 Lysando Ag Antimicrobial agents against salmonella bacteria
BR112019007979A2 (pt) * 2016-10-20 2019-07-09 Lysando Ag novos agentes antimicrobianos contra bactérias enterococcus
WO2018185634A1 (en) * 2017-04-03 2018-10-11 Sasinapas Co., Ltd. Engineered gram-negative endolysins
CN108018271B (zh) * 2018-01-31 2020-08-11 武汉核圣生物技术有限公司 单亚基rna聚合酶、其纯化方法及在rna合成中的应用
CN112368376A (zh) * 2018-03-29 2021-02-12 康特拉费克特公司 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途
AU2019276253A1 (en) * 2018-05-30 2020-11-26 Lysando Ag Novel antimicrobial proteins
KR20210049023A (ko) * 2018-08-23 2021-05-04 콘트라펙트 코포레이션 리신-항미생물 펩타이드(amp) 폴리펩타이드 작제물, 리신, 이를 인코딩하는 단리된 폴리뉴클레오타이드 및 이의 용도
US20230106068A1 (en) * 2020-03-02 2023-04-06 Conopco, Inc., D/B/A Unilever An effective anti-acne personal care composition
CA3171721A1 (en) 2020-03-19 2021-09-23 Fritz Eichenseher A stabilized protein of interest
EP4289949A1 (en) 2021-02-08 2023-12-13 Wuhan Lysigen Bio-Tech Company Limited Bacteriophage lysine, chimera thereof and application thereof
WO2022225267A1 (ko) * 2021-04-19 2022-10-27 엠브릭스 주식회사 보툴리늄 독소 전위 도메인 및 엔도라이신을 포함하는 단백질 복합체 및 이를 포함하는 항균 조성물
WO2023168418A1 (en) * 2022-03-03 2023-09-07 Massachusetts Institute Of Technology Cell-wall binding protein specifically targeting cutibacterium acnes
CN114540385B (zh) * 2022-03-21 2023-06-23 齐鲁工业大学 一种利用大肠杆菌产溶葡萄球菌酶的方法
CN114349870B (zh) * 2022-03-21 2022-06-03 天津辅元生物医药科技有限公司 一种兼具防粘连功效的重组抗菌肽及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2132088A (en) 1987-07-06 1989-01-30 Louisiana State University Agricultural And Mechanical College Inhibition of eucaryotic pathogens and neoplasms and stimulation of fibroblasts and lymphocytes with lytic peptides
GB8816693D0 (en) 1988-07-13 1988-08-17 Agricultural & Food Res Viral enzyme & gene
GB2255561B (en) 1991-04-20 1995-06-21 Agricultural & Food Res Lysins from bacteriophages
DE69332740T2 (de) 1992-08-21 2004-02-05 The University Of British Columbia, Vancouver Kationische peptide und verfahren zu deren herstellung
PT778733E (pt) 1994-09-01 2001-06-29 Novozymes As Composicao proteica basica para matar ou inibir celulas microbianas
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US6428784B1 (en) 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US20030113298A1 (en) 1997-10-31 2003-06-19 Vincent Fischetti Use of bacterial phage associated lysing proteins for the prophylactic and therapeutic treatment of various illnesses
US6288212B1 (en) 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
US5993809A (en) * 1998-11-18 1999-11-30 Children's Hospital Medical Center Lysozyme fusion proteins in infections
WO2001000855A1 (en) 1999-06-23 2001-01-04 Ppl Therapeutics (Scotland) Ltd. Fusion proteins incorporating lysozyme
US7338936B2 (en) 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
EP1501935B1 (en) 2002-04-22 2009-09-23 Dow Global Technologies Inc. Low-cost production of peptides
US7566447B2 (en) 2003-05-15 2009-07-28 Iogenetics, Llc Biocides
EP1680503B1 (en) 2003-09-11 2011-06-22 Novozymes Adenium Biotech A/S Recombinant production of antimicrobial agents
WO2005108563A2 (en) 2004-04-19 2005-11-17 University Of Chicago Peptidoglycan-hydrolyzing protein encoded by bacteriophage n4
US7572602B1 (en) 2004-12-03 2009-08-11 The United States Of America As Represented By The Secretary Of Agriculture Nucleic acid encoding endolysin fusion protein
DE102005040347A1 (de) 2005-08-25 2007-03-01 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von Listerien
ES2346808T3 (es) 2006-03-31 2010-10-20 The University Court Of The University Of St. Andrews Composiciones antimicrobianas que comprenden un peptido cationico y una endopeptidasa de glicilglicina.
DE102006061002A1 (de) 2006-12-22 2008-06-26 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien
US9296789B2 (en) * 2007-09-25 2016-03-29 Pastoral Greenhouse Gas Research Ltd. Vaccines and vaccine components for inhibition of microbial cells
US20100310522A1 (en) 2007-11-26 2010-12-09 Plant Bioscience Limited Novel Polypeptides Having Endolysin Activity and Uses Thereof
US8481289B2 (en) 2008-07-24 2013-07-09 The United States Of America, As Represented By The Secretary Of Agriculture Triple acting antimicrobials that are refractory to resistance development
EP2157100A1 (en) * 2008-08-19 2010-02-24 Profos AG Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
US8389679B2 (en) * 2009-02-05 2013-03-05 The Regents Of The University Of California Targeted antimicrobial moieties
DE102010014867A1 (de) * 2009-04-17 2010-11-18 Sms Siemag Ag Verfahren zum Bereitstellen mindestens einer Arbeitswalze zum Walzen eines Walzguts
US8383102B2 (en) 2009-05-21 2013-02-26 The United States Of America As Represented By The Secretary Of Agriculture Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens
KR101701890B1 (ko) 2009-06-26 2017-02-02 뤼산도 아게 항균제
KR20170024129A (ko) 2009-06-26 2017-03-06 카톨리에케 유니버시테이트 루벤 항균제
MX2012002216A (es) 2009-08-24 2012-04-10 Univ Leuven Kath Nueva endolisina obpgplys.
MX340520B (es) 2010-04-27 2016-07-12 Lysando Ag * Metodo de reduccion de biopeliculas.
US9388400B2 (en) * 2012-06-29 2016-07-12 Lysando Ag Composition for use in mycobacteria diagnosis

Also Published As

Publication number Publication date
EP2446028B1 (en) 2018-04-04
CN102482655A (zh) 2012-05-30
JP2012530510A (ja) 2012-12-06
EP3363896A1 (en) 2018-08-22
JP2017018092A (ja) 2017-01-26
CA2765810A1 (en) 2010-12-29
US20120195872A1 (en) 2012-08-02
BRPI1015203A2 (pt) 2016-08-02
EA201270082A1 (ru) 2012-06-29
US20190218538A1 (en) 2019-07-18
CA2765810C (en) 2018-10-16
JP6034188B2 (ja) 2016-11-30
IL217121A0 (en) 2012-02-29
AU2010264659A1 (en) 2011-12-15
KR20120061802A (ko) 2012-06-13
WO2010149795A1 (en) 2010-12-29
AU2010264659B2 (en) 2016-08-04
IL217121B (en) 2019-08-29
CN102482655B (zh) 2018-04-10
EP2446028A1 (en) 2012-05-02
EA038542B1 (ru) 2021-09-13
US11136570B2 (en) 2021-10-05
BRPI1015203B1 (pt) 2021-06-01
KR101701890B1 (ko) 2017-02-02
SG177704A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
MX2011013453A (es) Agentes antimicrobianos.
MX2011013288A (es) Agentes antimicrobianos.
MX344257B (es) Agentes antimicrobianos.
AU2010288559A8 (en) New endolysin OBPgpLYS
GB201018518D0 (en) Novel endolysin
WO2010023207A3 (en) Antimicrobial agents
MX340520B (es) Metodo de reduccion de biopeliculas.
Mercer et al. Antimicrobial susceptibility testing of antimicrobial peptides to better predict efficacy
Sojka et al. Antibiofilm efficacy of honey and bee-derived defensin-1 on multispecies wound biofilm
Menousek et al. Database screening and in vivo efficacy of antimicrobial peptides against methicillin-resistant Staphylococcus aureus USA300
JP2014500714A5 (es)
JP2012530510A5 (es)
EA201991233A1 (ru) Новый эндолизин
WO2011110655A3 (en) Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease
KR102573154B1 (ko) 변성 펩티드
MX2019011808A (es) Endolisinas de gram-negativas modificadas.
EP3313862B9 (en) Broad-spectrum anti-infective peptides
Ho et al. Bacteriophage endolysins against gram-positive bacteria, an overview on the clinical development and recent advances on the delivery and formulation strategies
Da Silva et al. Antibacterial activity of a novel antimicrobial peptide [W7] KR12-KAEK derived from KR-12 against Streptococcus mutans planktonic cells and biofilms
BR112014027629A2 (pt) misturas de polipeptídeo com atividade antibacteriana
Heinzinger et al. Evaluating the Translational Potential of Bacteriocins as an Alternative Treatment for Staphylococcus aureus Infections in Animals and Humans
PL243303B1 (pl) Rekombinowany polipeptyd do zastosowania do leczenia, kompozycje go zawierające oraz jego zastosowania
Lewies An in vitro evaluation of the antibacterial and anticancer properties of the antimicrobial peptide nisin Z
TH120357B (th) สารต้านจุลินทรีย์
TH120358B (th) สารต้านจุลินทรีย์

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ELANCO ANIMAL HEALTH IRELAND LIMITED

FG Grant or registration